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Noninvasive molecular tests of urine cells have been
developed to monitor the activity of kidney diseases. We
evaluate whether measurement of urinary messenger RNA
(mRNA) levels of chemokine and growth factor genes could
distinguish between diffuse proliferative lupus nephritis
(class IV LN) and others and whether it is able to predict the
response to therapy. Prebiopsy urine samples were collected
from 26 LN patients. Urine specimens were serially collected
over a period of 6 months from class IV LN patients who were
receiving standard immunosuppressive treatments. Urinary
interferon-producing protein 10 and its CXC chemokine
receptor (CXCR)3, transforming growth factor-b (TGF-b), and
vascular endothelial growth factor (VEGF) mRNA levels were
analyzed by quantitative real-time polymerase chain reac-
tions. Levels of chemokine or growth factor mRNAs in urine
could distinguish class IV LN from others, with a sensitivity of
85% and a specificity of 94%. The receiver-operative
characteristic curve demonstrated that urine mRNA levels of
these genes could identify active class IV LN with an accuracy
greater than the current available clinical markers, namely
systemic lupus erythematosus (SLE) disease activity index,
proteinuria, renal function, or urinalysis. A significant
reduction of interferon-producing protein 10 (IP-10), CXCR3,
TGF-b, and VEGF mRNA levels from baselines was observed in
patients who responded to therapy, whereas the levels
tended to increase in those who resisted to treatment.
Measurement of urinary chemokine and growth factor
mRNAs can precisely distinguish class IV LN from others.
Temporal association between these markers and therapeu-
tic response is demonstrated. This noninvasive approach
serves as a practical tool in diagnosis and management of LN.
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Clinical manifestations of lupus nephritis (LN) could vary
from asymptomatic urinary abnormalities to rapidly pro-
gressive renal failure. Severity of LN can fluctuate during the
course of the disease and treatment; thus, it requires serial
monitoring.1,2 Although urinalysis or quantification of
urinary protein levels is simple and may aid the diagnosis,
it cannot distinguish among various LN classes. Assessments
of serum auto-antibodies and complement levels also have
limited value.3–5 Knowing the nature or type of glomerular
pathology is crucial in predicting the prognosis of the
patients. For example, a patient with class IV LN usually
turns into an advanced state of chronic kidney disease within
a few months, whereas a class II or class V patient may
maintain nearly normal renal function.4 Therefore, kidney
biopsy is necessary not only for establishing the diagnosis but
also for confirmation of relapse.3,6 Although essential,
repeated renal biopsy is not practical due to its invasiveness
and potential unacceptable complications. Therefore, a
noninvasive tool to monitor relapse as well as to guide
treatment decision is extremely warranted.
Substantial evidence suggests that T-helper 1 (Th-1) type
chemokines, in particular g-interferon-inducible protein (IP-
10), contribute to the inflammatory cell infiltration of
affected organs in SLE patients.7,8 IP-10 is expressed and
secreted by monocytes and endothelial cells. In a lupus
mouse model, this chemokine regulates the Th1-cell migra-
tion into kidney and lung via interaction with CXC
chemokine receptor (CXCR)3.8 Neutralizing mono-
clonal antibodies or small-molecule inhibitors that disrupt
CXCR3 function markedly attenuates the inflammatory
response, resulting in reduction of kidney damages.9,10 In
human SLE, serum levels of IP-10 protein were high,
particularly in patients with active nephritis.11 The increased
urinary levels of monocyte chemoattractant protein-1 and
IFN-g proteins in active LN patients support the pathological
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roles of these Th-1 type chemokines.12,13 Growth and
sclerosing factors such as transforming growth factor-b
(TGF-b) may also play a pivotal role in the initiation of
inflammation and the progression of renal fibrosis.14–16 TGF-
b is a potent inducer of vascular endothelial growth factor
(VEGF) expression.17,18 VEGF can increase vascular perme-
ability and lead to proteinuria. Coexpression of both genes
has been demonstrated in renal tissue containing accelerated
tissue repair and fibrosis.19 One study has revealed increased
VEGF gene expression in both plasma and renal tissue from
LN patients.20
Determination of cytotoxic T-lymphocyte messenger
RNAs (mRNAs) of urine cells has been shown to be useful
in the diagnosis of acute renal allograft rejection.21 Similarly,
urinary mRNAs of some Th-1 cytokines, chemokines, and
growth factors correlate with SLE disease activity index
(SLEDAI) and clinically defined renal flare. However, this
approach cannot precisely distinguish diffuse proliferative LN
(class IV LN) from other types.12,13 Importantly, 15–20% of
patients with class IV LN respond poorly to the standard
therapy and cannot be predicted by currently available
markers.22–24 Therefore, a new surrogate marker is needed.
Measuring mRNA from urine cells can partly reflect the
molecular milieu of the whole kidney.21,25 Thus, the levels of
such gene candidates could be employed to study pathophy-
siologic mechanisms and disease processes. Fluctuating levels
of the urinary mRNA of some genes may be markers of the
severity or chronicity of the disease. The present study is
aimed to determine whether the mRNA levels of chemokine
IP-10 or CXCR3 and growth factor TGF-b or VEGF in urine
cells could be applied individually or in combination for
routine clinical use.
RESULTS
Patient characteristics
We studied urine samples (n¼ 52) at baseline from 26
patients. In all, 10 urine samples from healthy females served
as controls. The demographic and clinical data of studied
patients are summarized in Table 1. There were 14 patients
with class IV, three with class II, three with class III, four with
class V, and two with class VI LN. The mean7standard
deviation of baseline pathological activity and chronicity
indices for class IV group were 1276 and 474, respectively.
Elevation of urinary chemokine, IP-10, and CXCR3, mRNA
levels in class IV LN
The mRNA levels of chemokine, IP-10, and CXCR3 in
urinary cells were higher in patients with class IV LN as
compared with those in other classes (2.4470.14 vs
1.0670.19; Po0.001 and 1.8170.17 vs 0.9970.16 copies/
mg total RNA; P¼ 0.002, respectively) (Figure 1a and b). The
natural log-transformed chemokine mRNA levels were used
as the dependent variable in one-way ANOVA to test the
differences between the LN classes. The urinary IP-10 and
CXCR3 mRNA levels from patients with class IV LN,
measured within 2 weeks before renal biopsy, were sig-
nificantly higher compared to those of class II, III, V, and VI
(Table 2). No significant difference of the housekeeping gene
18s receptor RNA (rRNA) levels was observed among the five
Table 1 | Patient characteristicsa
Class IV Other classes P-value
Number 14 12 (3:3:4:2) (II:III:V:VI)
Number of urine samples 28 24
Age (year) 2971 3072 0.95
Gender (F/M) 13/1 10 0.90
Serum creatinine (mg/dl) 1.4870.35 1.4470.25 0.92
Creatinine clearance (ml/min) 62.977.2 48.479.4 0.23
Proteinuria (g/day) 2.270.5 2.870.7 0.43
Urinary erythrocyte count (per high power) 2879.0 1476.9 0.22
SLEDAI 6.870.9 5.471.0 0.32
Steroid dosage (mg/day) 3376 3077 0.75
aThe groups of patients were identified by kidney biopsy based on WHO classification.
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Figure 1 | Levels of mRNA in urine cells. Dots and bars show
(log)mRNA levels and means for (a) IP-10, (b) CXCR3, (c) TGF-b, and
(d) VEGF in urine samples from patients classified as having class IV
LN or non-class IV LN. The levels of IP-10 (Po0.001), CXCR3
(P¼ 0.002), TGF-b (Po0.001), and VEGF (Po0.001) were significantly
higher in patients with class IV than in patients with other classes of
LN.
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groups (P¼ 0.56). The urinary mRNA levels of IP-10 and
CXCR3 were not detected in the controls (data not shown).
Elevation of urinary growth factor, TGF-b, and VEGF, mRNA
levels in class IV and class VI (diffuse glomerulosclerosis) LN
The mRNA levels of growth factor, TGF-b, and VEGF in
urine cells were higher in patients with class IV LN as
compared with those in other LN classes (3.2470.13 vs
1.8170.26; Po0.001 and 2.3970.20 vs 0.9970.29 copies/mg
total RNA; Po0.001, respectively) (Figure 1c and d). The
urinary TGF-b and VEGF mRNA levels from patients with
class IV LN, measured within 2 weeks before renal biopsy,
were significantly higher compared with class II, III, and V.
However, there was no significant difference between the
mRNA levels from class IV and class VI LN (Table 2).
Interestingly, the two patients of class VI LN formerly had
biopsy-proven class IV LN. Both had a history of multiple
nephritis flares and had progressive deterioration of renal
function despite aggressive immunosuppressive therapy.
Urine chemokine and growth factor mRNAs distinguish class
IV LN from other LN classes
The receiver-operator characteristic (ROC) curves (Figure 2)
depicted the true positive fractions (sensitivity) and false-
positive fractions (1specificity) at various cut points for
mRNA levels for IP-10, CXCR3, TGF-b, and VEGF (Figure
2a) and other diagnostic markers: SLEDAI, creatinine
clearance, 24-h urine protein excretion, urinary leucocytes,
and erythrocytes (Figure 2b). The natural log-transformed
cut point (threshold) that maximized the combined sensi-
tivity and specificity for IP10, CXCR3, TGF-b, and VEGF was
2.09, 1.65, 2.50, and 1.82 copies/mg total RNA, respectively. At
these thresholds, the sensitivity and specificity were 73 and
94% for IP-10, 65 and 83% for CXCR3, 85 and 83% for TGF-
b, and 77 and 76% for VEGF, respectively. The calculated area
under the ROC curve for IP-10 was 0.89 (95% confidence
interval¼ 0.78–0.99), for CXCR3 was 0.79 (95% confidence
interval¼ 0.65–0.93), for TGF-b was 0.87 (95% confidence
interval¼ 0.76–0.97), and for VEGF was 0.82 (95% con-
fidence interval¼ 0.68–0.96). Given the fact that class VI LN
can probably be recognized by prebiopsy parameters such as
treatment failure and irreversible deterioration of renal
function, it might be interesting to assess the usefulness of
these markers by leaving out the class VI patients from the
analyses. Indeed, removing class VI from the analyses
increased diagnostic accuracy of these genes, particularly
TGF-b and VEGF. The sensitivity and specificity increased to
85 and 94% for TGF-b and 85 and 84% for VEGF,
respectively.
Figure 2b shows the ROC curves for other conventional
diagnostic markers with respect to class IV LN. Comparing
with the urine mRNA levels, these markers poorly discrimi-
nated class IV LN from other classes of LN, as could be
demonstrated by the calculated area under the curve at 0.598,
0.554, 0.536, 0.589, and 0.741 for SLEDAI, creatinine
clearance, 24-h urine protein excretion, urinary leucocytes,
and erythrocytes, respectively.
Pearson correlation analysis revealed that there was a
significant correlation between IP-10 and CXCR3 mRNA
levels in urine (R¼ 0.78, Po0.001). There was a correlation
between TGF-b and VEGF mRNA levels in urine as well
(Figure 3a and b) (R¼ 0.877, Po0.0001).
An overlapping of urinary mRNA levels between class IV
and other classes (Figure 1) was observed in three patients.
Among non-class IV group, two of class VI and one of class
III patients showed mRNA levels comparable to those of class
IV LN. Using the threshold levels described above, the
Table 2 | Levels of mRNA in urine cellsa,b
Class II Class III Class IV Class V Class VI P-value
IP-10 0.8670.27 1.5570.50 2.4470.14 1.2570.26 1.170.1 o0.001
CXCR3 1.1270.26 1.5370.24 1.8170.17 0.8470.20 0.570.1 0.005
TGF-b 1.6470.26 2.070.52 3.2470.13 1.4070.44 3.0370.38 o0.001
VEGF 0.2770.27 1.9170.15 2.3970.20 0.2970.29 3.0370.62 o0.001
aData expressed as mean7s.e.m. of log copies/mg total RNA.
bThe groups of patients were identified by kidney biopsy based on WHO classification.
IP-10: interferon-producing protein 10, TGF-b: transforming growth factor-b, VEGF: vascular endothelial growth factor.
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Figure 2 | ROC curves of mRNA levels and other diagnostic
markers. The fraction of true-positive results (sensitivity) and that
false-positive results (1specificity) for (a) IP-10, CXCR3, TGF-b, and
VEGF mRNA levels, and (b) other diagnostic markers as markers of
class IV LN are shown. The calculated area under the curve was 0.89
for IP-10, 0.79 for CXCR3, 0.87 for TGF-b, 0.82 for VEGF mRNA levels,
0.598 for SLEDAI, 0.554 for creatinine clearance, 0.536 for 24-h urine
protein, 0.589 for urine leukocyte count, and 0.741 for urine
erythrocyte count. A value of 0.5 (reference line) is no better than
expected by chance and a value of 1.0 reflects a perfect indicator.
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patients with class VI LN had high urinary levels of TGF-b
and VEGF, but not IP-10 and CXCR3 mRNAs. One patient
with class III LN had high urinary levels of all studied genes.
Interestingly, this patient had subsequently developed class
IV LN despite steroid therapy and required a potent
immunosuppressive regimen a few months later.
Serial monitoring of urinary chemokines and growth factor
mRNA levels predicts response to therapy
Serial measurements of urine mRNA levels were performed
monthly from baseline to the fifth month in 10 responders
and four nonresponders of class IV LN according to the
criteria described below. The baseline mRNA levels did not
significantly differ between these two groups. The IP-10,
CXCR3, TGF-b, and VEGF mRNA levels were markedly
reduced in the responder group after treatment (Figure 4a)
(P-value¼ 0.01, 0.05, 0.01, and 0.03, respectively). In
contrast, the IP-10, CXCR3, TGF-b, and VEGF mRNA levels
tended to increase in the nonresponder group (Figure 4b)
(P-value¼ 0.85, 0.66, 0.65, and 0.46, respectively). All
patients in the nonresponder group had additional kidney
biopsies, which showed worsening of renal pathologies. One
of these patients developed crescentic glomerulonephritis
with diffuse proliferative nephritis.
DISCUSSION
Successful management of LN requires a prompt diagnosis
and early treatment. Abnormal urine sediments or protein-
uria regardless of its degree or pattern (persistently or
episodically) may be found in association with progressive
renal pathology despite stable renal functions. Multiple
urinary biomarkers have been shown to correlate with
clinical criteria such as SLEDAI or clinically defined renal
flare.12,13,26 The present study verifies the potential utility of
novel urinary biomarkers in patients who had pathologically
confirmed proliferative (class IV) LN. Importantly, the
application can be extended to the use in early prediction
of therapeutic response in class IV LN patients. It should be
emphasized that the class IV LN patients require potent
immunosuppressive treatment. This monitoring tool may
provide a better optimization of immunosuppressive agents
in order to avoid their toxicities.
In this study, the measurement of urinary mRNA levels of
IP-10 and CXCR3 chemokine genes, and TGF-b and VEGF
growth factor genes is practical and should be useful in
diagnosing class IV LN and in predicting clinical therapeutic
response with high sensitivity and specificity. IP-10 appears
to be the best candidate, followed by TGF-b, despite the fact
that some overlapping levels of these mRNA can occur
among patients with class IV and others, particularly class VI
(diffuse glomerulosclerosis) (Figure 1). It should be noted
that the two patients of class VI LN actually transformed
from class IV LN and they showed resistance to prior
cytotoxic therapy. Interestingly, the patients with class VI LN
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Figure 3 | Coordinated expression of mRNAs for chemokines and
growth factors in urine cells. (a) The relationship between the levels
of IP-10 and CXCR3 was significant at Po0.0001 (R¼ 0.78). (b) The
TGF-b and VEGF urinary mRNA was significantly correlated at
Po0.0001 (R¼ 0.88).
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Figure 4 | Changes in urinary mRNA levels of IP-10, CXCR3, TGF-b, and VEGF over the 6-month period of treatment in patients with LN
class IV. Dots and bars show means and s.e.m.’s of (log)mRNA levels for IP-10, CXCR3, TGF-b, and VEGF in urine samples from baseline through
the fifth month of treatment. (a) The levels of IP-10, CXCR3, TGF-b, and VEGF were significantly decreased in the responder group, (b) whereas
the levels of these genes were not changed in the nonresponder group.
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had high urinary mRNA levels of TGF-b and VEGF, but not
of IP-10 and CXCR3. The above findings suggest that the
growth factors, not chemokines, reflect an ongoing process of
tissue repair and fibrosis in the kidney. In contrast, the
patient with class III (focal proliferative), which subsequently
progressed into class IV, LN showed high urinary mRNA
levels of both chemokines and growth factors. Taken together,
monitoring of urine cells gene expression with combined
biomarkers may serve as a reliable tool to distinguish class IV
LN from other classes.
Currently, renal histopathologic study is the standard
method of determining the presence of inflammatory process
in nephritis patients. However, studying renal pathology may
not give details on the progression of nephritis over a time
span unless the hazardous renal biopsies are repeated.
Monitoring gene expression in urine cells over time gives
additional information, which would be complementary to
the pathological study in understanding the ongoing
inflammatory process of nephritis. Increased urinary mRNA
levels of IP-10 and CXCR3 in only class IV LN support the
role of Th-1 chemokines in intrarenal inflammation.
Alternatively, the upregulation of TGF-b and VEGF in class
IV and VI (diffuse glomerulosclerosis) may reflect tissue
repair and fibrosis. It would be of interest to study whether
molecular signaling could predict long-term renal function.
Although the present cohort’s follow-up period was short, we
believe that the highly sustained expression of IP-10 and
CXCR3 distinguishes an ongoing renal inflammation. In
agreement with the study reported by Rovin et al.,26 serial
measurement of urine chemokine, monocyte chemoattrac-
tant protein-1 protein, predicts clinical renal flare and
response to therapy in their prospective study. It remains
intriguing as to which parameters could predict long-term
renal function. Upregulation of TGF-b and VEGF found in
class IV and VI in this report may reflect tissue repair and
fibrosis. Alternatively, such persistent expression may predict
poor outcome in the future, with sclerosis and fibrosis of the
entire kidney.
Multiple conventional markers as shown here, such as
proteinuria and SLEDAI, ineffectively discriminate class IV
LN from others. Only urine erythrocyte count can reliably
distinguish class IV renal pathology. Nevertheless, variable
numbers of urine erythrocyte counts could be found in most
female patients during each visit. Therefore, the presence of
erythrocyte in urine cannot predict the response to
treatment. There are pressing needs for a short-term LN
treatment trial to compare the outcome, since current
management relies on more rigid criteria, such as renal or
patient survival, which require at least 5 years to complete.
Given the key functions of the studied genes, the measure-
ment of their gene transcripts may replace the conventional
markers being used as surrogate markers in the clinical trials
of molecularly targeted therapy such as cytokine or growth
factor blockade.
Repeated attacks of LN, particularly diffuse nephritis, is
the worst prognostic factor in the development of end-stage
renal disease.5 Most SLE patients, however, die from
complications and infections partly from overuse of im-
munosuppressive agents. The monitoring of urine cell
chemokines and growth factors described herein may be
another useful approach for early detection of the critical
stage of inflammation in the kidney of SLE patients and for
tailoring immunosuppressive therapy.
MATERIALS AND METHODS
Patients
In total, 26 patients who had been diagnosed with SLE according to
the American College of Rheumatology diagnostic criteria for SLE
were recruited between August 2002 and September 2004. A total of
52 urine samples were obtained. Two urine samples were collected
from each individual patient approximately 2 weeks and 1 day
before renal biopsy. Renal involvement was documented by having
one of the following criteria: a total urinary protein level of more
than 0.5 g/day, an increment of serum creatinine levels of more than
0.5 mg/dl during 1 month period of follow-up, or presence of
pyuria, hematuria, or urinary cast by microscopic examination. All
biopsy specimens were examined by one pathologist (VK) who was
not aware of the results of the molecular study. Using the
classification of the histologic types of LN by World Health
Organization,27,28 14 of 26 biopsy specimens were identified as
class IV, whereas the remaining 12 specimens were categorized into
other classes. All 26 patients received prednisolone (0.5 mg/kg/day)
without other cytotoxic drugs, prior to renal biopsy for at least 1
month. Four patients received 5–10 mg per day of enalapril. In all, 10
urine samples from healthy women served as controls.
This study has been approved by the Ethics Committee for
Human Research of the Faculty of Medicine, Chulalongkorn
University, and written informed consents were obtained from all
subjects.
Of the 26 patients, 14 patients with class IV LN were
prospectively followed. These patients received oral prednisolone
at the dosage of 0.5 mg/kg/day plus a 6-month regimen of either
monthly intravenous pulse cyclophosphamide or oral mycopheno-
late mofetil. Urine samples were collected monthly from pretreat-
ment baseline to the fifth month of treatment. Therapeutic response
was defined either by the improvement of pathological scores of
activity and chronicity based on repeated kidney biopsies, or by the
following clinical criteria, including: (1) stabilization or improve-
ment in renal function; (2)X50% decrease in hematuria to less than
10 RBC per high-power field; and (3) significant reduction in
proteinuria (X50% decrease to less than 3 g/day if baseline
nephrotic range, p1 g/day if baseline non-nephrotic) for at least 3
months.29
Collection of urine sample and RNA isolation
Urine was immediately centrifuged after collection at 1000 g for
30 min at 41C. Total RNA was isolated from the cell pellets using an
RNA blood mini kit (Qiagen, Chatworth, CA), measured for
concentration and reverse-transcribed into complementary DNA as
described previously.21
Analysis of urinary mRNAs
The mRNA levels of IP-10, CXCR3, TGF-b, VEGF, and the
housekeeping gene, 18s rRNA, were measured by a Light Cycler
machine (Roche Molecular Biochemicals, Indianapolis, IN). The
sequences of primers and fluorescence probes are as follows: IP-10
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sense 50att ttg tcc acg tgt tga gat ca30, IP-10 antisense 50tgg cct tcg att
ctg gat tc30 and IP-10 probe 50 6-carboxy-fluorescein (FAM) aca tct
ctt ctc acc ctt ctt ttt cat tgt agc a 6-carboxy-tetramethylrodamine
(TAMRA)30; CXCR3 sense 50acc cag cag cca gag cac30, CXCR3
antisense 50caa cct cgg cgt cat tta gc30, and CXCR3 probe 50FAM ctt
ggt ggt cac tca cct caa gga cca t TAMRA30; TGF-b sense 50ccc tgc ccc
tac att tgg ag30, TGF-b antisense 50 ccg ggt tat gct ggt tgt aca30, and
TGF-b probe 50FAM cac gca gta cag caa ggt cct ggc c TAMRA30;
VEGF sense 50cct aca gca caa caa atg tga atg30, VEGF antisense 50 caa
atg ctt tct ccg ctc tga30, and VEGF probe 50FAM caa gac aag aaa atc
cct gtg ggc ct TAMRA; 18s rRNA sense 50gcc cga agc gtt tac ttt ga30,
18s rRNA antisense 50tcc att att cct agc tgc ggt atc30, and 18s rRNA
probe 50FAM aaa gca ggc ccg agc cgc c TAMRA30. The probes were
labeled with FAM at the 50 end, and with TAMRA at the 30 end. FAM
serves as the reporter dye, and TAMRA serves as the quencher dye.
All primer pairs were designed to span across an intron–exon
boundary to distinguish an amplification of genomic DNA. Each
polymerase chain reaction was set up for 20 ml reaction volume
comprising of 18 ml of polymerase chain reaction mastermix (Roche
Molecular Biochemical, Mannheim, Germany), 2 ml of complemen-
tary DNA template (diluted 1:1000 for 18s rRNA), 600 nM of primer,
and 200 nM of probe. Polymerase chain reaction amplification
included an initial denature at 951C for 2 min, followed by heating
at 951C for 10 s and 601C for 10 s repeated for 40 cycles. The TGF-b
and VEGF plasmids (kindly provided by Karumanchi SA, Harvard
Medical School, Boston, MA) and polymerase chain reaction
amplicon for 18s rRNA (kindly provided by Ding R, Cornell
University, New York, NY) were used for developing standard
curves. The standard curves were based on the principle that a plot
of the log of the initial target copy of a standard vs threshold cycles
results in a straight line. Levels of mRNA were expressed as number
of copies per microgram of total RNA isolated from the urine cells.
Kidney biopsy
Kidney biopsy specimens were scored for activity and chronicity
index. The activity index was calculated from the sum of
semiquantitative manual scores (0–3 each) of the following
parameters: endocapillary hypercellularity, leucocyte infiltration,
subendothelial hyaline deposits, interstitial inflammation, necrosis,
and cellular crescents. Scores of the last two parameters were
counted double, yielding the total range for the activity index of
0–24. The chronicity index was the sum of scores of the following
parameters: glomerular sclerosis, fibrous crescents, tubular atrophy,
and interstitial fibrosis.30 The maximum score of the chronicity
index was 12.
Statistical analysis
Statistical analysis was performed using the SPSS software (version
11.5). The levels of all studied mRNAs deviated significantly from
normal distribution (Po0.001), which was substantially reduced by
the use of a log transformation. The natural log mRNA levels were
used as dependent variables in comparison for any variable
difference by Student’s t-test (between two groups) and one-way
analysis of variance with Bonferrini’s correction (between groups).
The relationship between the mRNA levels of each gene was
estimated with Pearson’s correlation. To distinguish class IV LN
from others, receiver operator characteristic curve analysis of mRNA
levels was used to determine the cutoff levels that maximized the
combined sensitivity and specificity. The area under the curve was
calculated, and sensitivity and specificity at the selected cutoffs were
determined.
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